How effective is cabozantinib in the treatment of bone metastases? Clinical Data and Application Guide

Cabozantinib has shown good efficacy in the treatment of bone metastasis cancer, especially for tumor types that are prone to bone metastasis such as renal cell carcinoma and thyroid cancer. Its main mechanism of action is to block the angiogenesis and proliferation of tumor cells by inhibiting signaling pathways such as VEGFR (vascular endothelial growth factor receptor), MET and AXL, and reduce tumor damage to bone tissue. In clinical studies, cabozantinib has been proven to reduce the incidence of bone-related events, such as pathological fractures and bone pain, and significantly improve patients' progression-free survival (PFS) and overall survival (OS).

In the study of prostate cancer bone metastasis, the COMET-1 clinical trial evaluated the efficacy of cabozantinib in patients with castration-resistant prostate cancer (mCRPC). The results showed that the drug can significantly reduce the activity of bone metastases, improve bone scan results, and reduce the level of bone pain in patients. In addition, another COMET-2 study showed that cabozantinib treatment can relieve severe bone pain, reduce opioid use, and further improve patients' quality of life. For patients with bone metastases from renal cell carcinoma, the METEOR trial confirmed that cabozantinib can significantly improve the progression-free survival (PFS) of patients compared with everolimus (Everolimus), and the control rate of bone metastases is higher.

In terms of clinical application guidelines, cabozantinib has been recommended by NCCN (National Comprehensive Cancer Network) and ESMO (European Society of Medical Oncology) for patients with bone metastases from advanced renal cell carcinoma, prostate cancer and thyroid cancer. Cabozantinib can be used as a second-line or third-line treatment option, especially for patients who are resistant to or have progressed to other standard treatments. In addition, cabozantinib has a certain alleviation effect on complications related to bone metastasis (such as fractures, bone marrow compression), so in a comprehensive treatment plan, it can be used in combination with radiotherapy or bisphosphonates to further improve the efficacy.

Reference:https://en.wikipedia.org/wiki/Cabozantinib